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 Abstract 
  Background/Aims:   Uromodulin-associated kidney disease (UAKD) is caused by uromodulin 
mutations and leads to end-stage renal disease. Our objective was to examine the epidemiol-
ogy of UAKD.  Methods:  Data from all UAKD families in Austria were collected. Patients included 
in the Austrian Dialysis and Transplantation Registry (OEDTR) with unclear diagnoses or genet-
ic diseases were asked whether they had (1) a family history of kidney disease or (2) had suffered 
from gout. Patients with gout and autosomal dominant renal disease underwent mutational 
analysis. Kaplan-Meier and Cox analysis was employed to estimate time to renal failure.  Results:  
Of the 6,210 patients in the OEDTR, 541 were approached with a questionnaire; 353 patients 
answered the questionnaire. Nineteen of them gave two affirmative answers. In 7 patients, an 
autosomal dominant renal disease was found; in 1 patient a UMOD mutation was identified. 
One family was diagnosed through increased awareness as a consequence of the study. At pres-
ent, 14 UAKD patients from 5 families are living in Austria (1.67 cases per million), and 6 of them 
require renal replacement therapy (0.73 per 1,000 patients). Progression to renal failure was sig-
nificantly associated with UMOD genotype.   Conclusion:   UAKD patients can be identified by a 
simple questionnaire. UMOD genotype may affect disease progression. 
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 Introduction 
  Uromodulin or Tamm-Horsfall protein is a 95-kDa glycoprotein consisting of 640 ami-
no acids, which are encoded by the   UMOD   gene on chromosome 16p12.3. Uromodulin is 
synthesized by the cells of the thick ascending limb and early distal convoluted tubular cells 
in the kidney   [1]  . The highly glycosylated molecule is an avid binder, and after being secret-
ed into the urine binds to several different constituents that include bacteria, crystals, and 
proteins. 
    Uromodulin mutations are found to be associated with three autosomal dominant con-
ditions, namely familial juvenile hyperuricemic nephropathy (FJHN1; MIM 162000); med-
ullary cystic kidney disease type 2 (MIM 603860), and glomerulocystic kidney disease (MIM 
609886)   [2–4]  . The majority of   UMOD   mutations cluster in exons 4.5 and 8   [5]   and cause re-
placement of cysteine residues, leading to misfolding of the uromodulin molecule, with the 
abnormal uromodulin becoming entrapped in the endoplasmatic reticulum of the cells of 
the thick ascending limb of the loop of Henle. Thus, these diseases, which on clinical pre-
sentation are hardly distinguishable from each other, may be referred to as uromodulin-as-
sociated kidney diseases (UAKDs)   [4, 6–10]  , and large intracellular deposits can be seen in 
renal biopsies of affected patients   [6]  . 
    Families with UAKD have been reported from the US, Austria, Spain, France, Portugal, 
the Czech Republic, the UK, Belgium, Germany, Switzerland, Latvia, Morocco, Japan, Tur-
key, and South Korea   [2, 3, 5, 6, 8, 10–24]  . However, we are unaware of any nationwide epi-
demiologic study of UAKD. Here, we present data on all Austrian families diagnosed with 
UAKD. We also demonstrate that with the use of the Austrian Dialysis and Transplant Reg-
istry (OEDTR) and a simple patient questionnaire it was possible to identify previously un-
diagnosed patients.
  Patients  and  Methods 
  This epidemiological study has two components. First, data from all Austrian UAKD 
families that had been diagnosed independently from the structured study described below 
were collected. Second, in 2001, an epidemiologic study to identify other UAKD families was 
conducted by utilizing the OEDTR, which includes   1  99% of all patients receiving chronic 
renal replacement therapy (RRT) in Austria. The study population was comprised of all pa-
tients reported in the OEDTR and alive on January 26, 2001. At the time of the study, the 
disease was referred to as familial juvenile hyperuricemic nephropathy (FJHN), as its cause 
was still unknown. All patients enrolled in the OEDTR gave informed written consent to 
data analysis. In a first step, we identified renal disease codes used by the European Dialysis 
and Transplantation Association Registry and the OEDTR which might include cases of 
FJHN. We further included only those patients who started RRT between 20–50 years of age. 
The codes and the number of coded OEDTR patients are given in  table 1  and shown in  figure 
1 . In a next step, we sent a list of patients identified by this process to each nephrology center 
that participates in the OEDTR. In a questionnaire, each patient was asked the following two 
questions: 
    (1)  Does anyone of your family members suffer from chronic kidney disease (CKD)? 
  (2)  Did you have gout in the years before dialysis was initiated? 
  A de-identified list with the answers was returned to the study center at the Medical Uni-
versity of Innsbruck, Austria. Patients who gave an affirmative answer to both questions 
were asked to provide a focused and detailed medical history to the patient’s nephrologists. 
In the presence of a family history compatible with autosomal dominant inheritance of re-149
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nal disease and after exclusion of another clear diagnosis, patients were approached and 
after giving written informed consent in accordance with the Austrian law, underwent ge-
netic testing for mutations in the uromodulin   (UMOD)   gene and the hepatocyte nuclear 
factor-1     (HNF-1    )  gene. The methods for DNA sequence analysis have been described pre-
viously   [10, 25]  .
  End-stage renal disease (ESRD) was defined as either initiation of RRT or death because 
of renal failure without preceding RRT. Time to ESRD was assessed by Kaplan-Meier analy-
sis and log-rank test, and Cox proportional hazard models stratified by UMOD genotype. 
IBM SPSS Version 19 was used for statistical analyses. 
  R e s u l t s  
 Screening  Study 
 A study flow chart is presented in  figure 1 . In January 2001, the OEDTR included 6,210 
patients, 2,797 on hemodialysis, 241 on peritoneal dialysis, and 3,172 with functioning re-
nal transplants. Of these 6,210 patients, 541 had one or more diagnoses potentially com-
patible with the presence of UAKD (  table 1  ). Questionnaires were sent out to all 49 centers 
involved in the care of these patients and returned by 48 centers. The one non-participating 
center cared for 107 patients; since no additional information was available from these sub-
  Fig. 1.   Study flow chart. Diagno-
sis codes are further detailed in 
table  1. HD = Hemodialysis; 
PD = peritoneal dialysis; TX = 
renal transplant. 150
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jects, they were excluded from further analysis. Of the remaining 434 patients, a total of 
334 patients (77%) answered either one or both questions with ‘No’, 81 patients (18.7%) did 
not provide any response at all, and 19 patients (4.3%) answered both questions affirma-
tively. Before proceeding to genotyping, patient responses to the questionnaire were reas-
sessed by the attending nephrologists involved in the direct care of the patient. This reas-
sessment revealed that 1 patient had unequivocally nephronophthisis type 1 and that the 
family histories in 10 patients were incompatible with autosomal dominant diseases. One 
patient was not genotyped because UMOD genotyping had been negative in a first-degree 
relative, who had been tested outside the study. Seven patients underwent sequencing of 
the   UMOD   gene and the   HNF-1     gene. In 1 patient, a novel   UMOD   Cys217Trp mutation 
could be identified (  fig. 2  ; family 4, patient 3:     1). None of the 7 patients had a mutation in 
the   HNF-1     gene.
    The epidemiologic survey was presented and discussed extensively at national nephrol-
ogy meetings and, thus, increased awareness for FJHN among Austrian nephrologists. This 
led to the diagnosis of another individual with CKD, gout, and a positive family history dur-
ing the study. A novel Cys223Arg  UMOD  mutation was identified in that patient ( fig. 2 ; fam-
ily 5, patient 2:    1). 
    Brief Description of UAKD Families 
  Independent of the screening study, 3 families were already diagnosed with UAKD. 
Thus, altogether, currently 5 families with UAKD comprising 14 patients live in Austria (  ta-
ble 2  ). Their pedigrees are shown in   figure 2  .
  Family  1  (Cys77Tyr) 
  A description of the family and mutation analysis of the   UMOD   gene has been reported 
previously   [13, 26, 27]  . The index case (3:     3) presented with gout and CKD stage III. Family 
history revealed that his maternal grandmother (1:     1), his mother (2:     2) and all of her sisters 
(2:    1;  2:   3;  2:   4;  2:    5) suffered from renal failure and gout. In addition, 3 of his cousins (3:    1;  3:   2; 
3:     4) have gout and CKD. One of his sons (4:     1) is currently clinically unaffected but carries 
the   UMOD   mutation and has low fractional uric acid excretion. 
Diagnosis Code Patients
(n = 541)
Chronic renal failure, etiology uncertain 00 249
Pyelonephritis, cause not specified 20 169
Pyelonephritis due to other cause 29 13
Interstitial nephritis due to other cause 30 11
Medullary cystic disease 43 9
Familial nephropathy unspecified 50 7
Hereditary nephropathy – other specified type 59 8
Renal vascular disease due to hypertension 72 39
Gout 92 2
Other identified renal disorders 99 34
R  enal diseases were classified according to the code used by the 
ERA-EDTA Registry.
Table 1.   Renal diagnoses 
compatible with the presence of 
UAKD included in the center 
survey151
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  Family  2  (Cys126Arg) 
  This family has also been reported previously   [13, 27, 28]  . Only 2 individuals, mother 
(2:     3) and son (3:     1), who currently live in Austria, are included in this report. The mother’s 
father (1:     1) and 2 of her siblings (2:    1;  2:    2) had died from renal failure. Patient 2:     3 is currently 
on hemodialysis and her son suffers from CKD stage III.
  Family  3  (Asp196Tyr) 
  The family has been described previously   [29]  . The mother (2:     1) suffers from CKD IV; 
in her daughter (3:     1), a genetic diagnosis of UAKD was made immediately after birth. Three 
other affected family members live in Latvia. The father (1:    1) is on hemodialysis, and her two 
half-brothers (2:    2;  2:    3) have CKD stages III and II, respectively.
  Fig. 2.   Family trees. Squares indicate males, circles indicate females, arrows indicate index cases; filled 
squares/circles indicate subjects with FJHN1; asterisks indicate patients with ESRD; deceased patients are 
crossed out. 152
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  Family  4  (Cys217Trp) 
  The index case (3:     1) was discovered during the nation-wide survey. The patient is a 
48-year-old female who developed ESRD at age 37 years. She received a living donor allograft 
from her mother and currently lives with a functioning renal transplant. Her father (2:    2), 
grandmother (1:     1), and aunt (2:     1) all died from renal failure.
  Family  5  (Cys223Arg) 
  The index case (2:     1) was identified through increased awareness of FJHN in the course 
of the epidemiologic study. The 51-year-old female patient suffers from recurrent gout and 
CKD stage III. Her mother (1:     1) developed ESRD at age 53 years. She received a renal al-
lograft 3 years later and died from breast cancer at age 60 years. 
Table 2.   Austrian families with UAKD: mutations, in vitro effects, and ESRD
Family Mutation In vitro effects of mutation (ref.) A  live Died 
with 
ESRD
Total 
(dead or 
alive) total  
(Austria)
with 
ESRD 
(Austria)
without 
ESRD 
(Austria)
abroad
1 Cys77Tyr Reduced apical secretion [8] 8 4 4 3 11
2 Cys126Arg ER retention, absence at plasma membrane, severely 
reduced maturation [7, 9]
211 3 5
3 Asp196Tyr (Asp196Asn) ER retention, partial expression at 
plasma membrane, reduced maturation [9]
202 3 5
4 Cys217Trp ND 1 1 0 3 4
5 Cys223Arg ER retention, low expression at plasma membrane, 
severely reduced maturation [9]
101 1 2
Total 14 6 8 3 10 27
ER   = Endoplasmatic reticulum; ND = not determined. For the Asp196Tyr mutation, which has not been tested in vitro, 
the results for the Asp196Asn mutation are shown. All five mutations are located within exon 4 of the UMOD gene.
Table 3. U  AKD patients included in the OEDTR (n = 7)
Family Patient Gender Age in 2011, years Encoded diagnosis Age at 
ESRD onset
years
Family 1 2:1 female 67 10 – Glomerulonephritis, histologically not examined 45
2:3 female 59 10 – Glomerulonephritis, histologically not examined 34
2:5 female 55 42 – Polycystic kidneys; infantile (medullary sponge kidney) 35
3:4 male 45 84 – Lupus erythematosus 29
Family 2 2:3 female 61 50 – Familial nephropathy, not specified (uromodulin 
storage disease)
59
Family 4 3:1 female 48 20 – Pyelonephritis, cause not specified 37
Family 5 1:1 female died at the age of 60 
from breast cancer
10 – Glomerulonephritis, histologically not examined 53153
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    Prevalence of UAKD in Austria 
  Table 3  shows a complete list of 7 patients (6 are alive, 1 is deceased due to breast cancer) 
which are included in the OEDTR. In  table 4 , clinical details as well as treatment of 8 patients 
not on RRT are summarized.
    Taken together, at present, 14 living patients from 5 families with UAKD are known in 
Austria. Given a population of 8.4 million, the estimated prevalence of UAKD is therefore 
1.67 cases per million population. Six out of these 14 patients currently require RRT. As the 
number of patients receiving RRT in Austria is at present 8,200, the estimated prevalence of 
UAKD is 0.73 per 1,000 RRT patients. Including patients who live in Latvia (3 patients from 
family 3; Asp196Tyr mutation) or suffered from ESRD and had died (10 patients), a total of 
27 UAKD patients with 5 different UMOD mutations were documented ( table 3 ). Renal cysts, 
another frequent finding in UAKD, were detected by ultrasound in 6 out of the 14 living 
Austrian patients.
    UAKD and Progression to ESRD 
  Mean age at ESRD for all the UAKD patients combined was 43.8 (95% CI 38.8–48.8) 
years. To investigate whether there was any genotype-phenotype correlation between  UMOD  
mutation and ESRD, Kaplan-Meier analysis (  fig. 3  ) and Cox proportional hazard modeling 
Table 4.   Austrian UAKD patients not on RRT (n = 8)
Family Patient Age
years
Gender Creatinine 
mg/dl
eGFR, ml/
min/1.73 m2
Gout Serum uric 
acid, mg/dl
FEUA 
%
Therapy
Family 1 3:1 35 male 1.1 75 yes 2.6 7.6 allopurinol, benzbromarone
3:2 22 male 1.8 53 yes 7.8 3.8 allopurinol
3:3 28 male 3.0 27 yes 7.7 3.6 allopurinol
4:1 8 male 0.7 148 no 4.2 6.6 none
Family 2 3:1 39 male 1.9 41 no 8.7 2.8 allopurinol, benzbromarone
Family 3 2:1 25 female 2.0 34 yes 6.6 3.6 allopurinol
3:1 2 female 0.33 161 no 5.6 4.6 allopurinol
Family 5 2:1  51 female 2.7 20 yes 3.6 4.0 allopurinol
e  GFR = Estimated glomerular filtration rate; FEUA = fractional excretion of uric acid.
  Fig. 3.  Kaplan-Meier curves stratified by uromodu-
lin amino acid change. Overall p = 0.039 (log-rank 
test). 154
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( table 5 ) were carried out for patients with different  UMOD  mutations. These analyses showed 
that time to ESRD varied significantly between the UMOD genotypes (p = 0.039, log-rank 
test;   fig. 3  ). Mean age at ESRD was 46 (95% CI 35.2–58) years with Cys126Arg, 48.5 (95% CI 
36.9–60.1) years with Cys217Trp, 37.4 (95% CI 32.7–42) years with Cys77Tyr, 53 years (95% 
CI not applicable) with Cys223Arg, and 36 years (95% CI not applicable) with Asp196Tyr 
  UMOD   mutations. Patients with the Cys217Trp and Cys223Arg   UMOD   mutations had a sig-
nificantly lower hazard ratio compared to patients with the Cys77Tyr  UMOD  mutation, whilst 
patients with the Asp196Tyr and Cys126Arg   UMOD   mutations did not have a significantly 
different hazard ratio compared to patients with the Cys77Tyr  UMOD  mutation ( table 5 ). Re-
sults were materially identical after adjustment for gender and generation (data not shown).
  Discussion 
  Our data shows that UAKD is a rare disease with a prevalence of 1.7 cases per million 
population and   !  1 case per 1,000 RRT patients. At the time of the epidemiologic survey, the 
disease was referred to as FJHN and its cause was still unknown. Our study includes only 
those families in whom FJHN is caused by an   UMOD   mutation (MIM 162000). FJHN is ge-
netically heterogeneous, and in addition to uromodulin mutations found in 40% of families, 
it can be caused by mutations in the renin   (REN)   gene (associated with early onset anemia, 
FJHN2, MIM 179820) or by splice-site mutations in the   HNF-1     gene (renal cysts and dia-
betes syndrome, MIM 189907), each found in 2.5% of families   [30–32]  . Recently, another 
locus linked to chromosome 2p22.1-p21 has been identified (FJHN3)   [25]  . Presently, UAKD 
comprises the allelic disorders FJHN1, medullary cystic kidney disease type 2, and glomeru-
locystic kidney disease, which are caused by mutations in the UMOD gene and share a large-
ly overlapping phenotype.
    Three of the 5 Austrian families described here were identified by clinical suspicion. 
Families 1 and 2 were diagnosed on clinical grounds before the genetic abnormalities involv-
ing   UMOD   mutations were known. Family 3 was also diagnosed on clinical grounds and a 
mutation in the   UMOD   gene was identified   [29]  .
    Families 4 and 5 were identified by this nationwide study in 2001 to identify further 
FJHN cases, proving that identification of such families is possible by an epidemiologic ap-
proach. This study was based on all RRT patients included in the OEDTR in 2001. Of note, 
  1  99% of all patients receiving chronic RRT in Austria are documented in the OEDTR   [33]  . 
We employed a three-pronged approach to ascertain potential patients with FJHN: (a) the 
presence of chronic RRT, (b) the presence of diagnoses deemed possible to comprise patients 
with FJHN, and (c) the presence of two characteristics of FJHN, namely a family history of 
renal disease and a history of gout. Both items can be determined by a simple questionnaire. 
Amino acid change b SE p value HR 95% CI of HR
Asp196Tyr 0.11 1.10 0.919 1.12 0.13–9.62
Cys126Arg –1.53 0.79 0.052 0.27 0.05–1.00
Cys217Trp –1.89 0.84 0.024 0.16 0.03–0.78
Cys223Arg –2.58 1.20 0.031 0.08 0.01–0.78
O  verall model fit, p = 0.054. b = Regression coefficient; SE = 
standard error; HR = hazard ratio.
Table 5. R  esults of the Cox 
proportional hazard model with 
Cys77Tyr as the reference group155
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For further work-up, the family history had to be compatible with autosomal dominant in-
heritance, and other clear diagnoses had to be excluded. The main drawback of the epide-
miologic study appeared to be step b, the selection of patients who eventually were asked to 
answer the questionnaire, based on the list of diagnoses (  table 1  ). We selected a group of di-
agnoses that might include FJHN cases and asked all patients who had started RRT between 
age 20 and 50 years. In retrospect, the selection of clinical diagnoses was not optimal. Mem-
bers of family 1 did not show up in our survey, because their disease was coded as ‘glomeru-
lonephritis not histologically examined’ and ‘lupus erythematosus’ ( table 4 ). Second, the age 
range when these patients develop ESRD is probably wider than assumed at the time of our 
study. For example, in family 1, individual 3:    4 developed ESRD at age 29 years ( table 4 ); how-
ever, individual 2:     1 in the same family with the same mutation is not yet on RRT at the age 
of 45 years (  table 3  ). Later reports found earlier as well as later onset of ESRD in UAKD   [6, 
19] . Affected family members may develop ESRD between childhood and the seventh decade 
of life. Two of the patients described here required dialysis at age 59 years (family 2, subject 
1:     1) and 53 years (family 5, subject 1:     1;   table 3  ). These patients would also not have shown up 
in our survey. Therefore, it is possible that we missed other patients suffering from FJHN 
included in the registry and, thus, that the prevalence reported by us may be too conserva-
tive. Another factor causing underestimation of UAKD prevalence may be the fact that we 
did not receive the questionnaire from 188 of the 541 patients selected by renal diagnosis. In 
addition, 10% of UAKD patients seem to have no family history of kidney disease, and one 
third of them does not suffer from gout   [5]  . 
    Our study also demonstrates that increased awareness of the disease may aid the diag-
nosis of UAKD, as exemplified by family 5. Furthermore, in the course of the study, 14 other 
families classified as or suspected of FJHN, but without UMOD mutations, have been identi-
fied, either by the epidemiological study itself or by increased awareness among nephrolo-
gists. These families enabled our identification of another genetic locus for FJHN linked to 
chromosome 2p22.1-p21 (FJHN3)   [25]  .
    We are not aware of a similar systematic study of the epidemiology of UAKD. Coming 
closest to such a study is the report of Vylet’al et al.   [8]   from the Czech Republic, who re-
ported 3 families with 16 patients, 3 of them requiring RRT. The calculated prevalence would 
be 1.52 patients per million population and 0.58 per 1,000 RRT patients in the Czech Repub-
lic; these estimates are in the same range as those reported here for Austria (1.67 per million 
population, and 0.73 per 1,000 RRT patients). Bollee et al.   [5]   reported on 109 patients from 
France and Belgium. The calculated prevalence for both countries together would be 0.7 per 
million population. Simmonds et al.   [34]   reported on 158 patients from 31 FJHN kindreds 
in Britain. Genetic analysis showed UMOD mutations in 6 out of 25 tested families. The 
number of patients with an UMOD mutation, however, is not given in that report.
    To put these numbers into perspective, it is interesting to compare them with the preva-
lence of Anderson-Fabry disease, which has also been studied systematically in Austrian 
RRT patients. In a study of 2,480 dialysis patients, 4 cases were identified by mutation anal-
ysis of the GAL gene (prevalence 1.6 per 1,000 RRT patients)   [35]  . Another report on 1,306 
male renal transplant patients identified 5 cases (3.8 per 1,000 patients)   [36]  .
  Progression to ESRD is highly variable and seems to be affected by the UMOD genotype. 
The basis of the suspected genotype-phenotype relationship is unclear. Our in vivo clinical 
findings did not correlate with the relative in vitro effects of the mutations, which have been 
reported by our group and others   [8–10]  . For example, in vitro, uromodulin mutation of the 
Cys126 and Cys223 residues showed that the most severe maturation defects being retained 
in the endoplasmatic reticulum and absent or markedly reduced at the plasma membrane 
  [10]   (  table 2  ), yet, were associated with the mildest clinical outcome in their association with 
the latest onset of ESRD (  fig. 3  ;   table 5  ). In contrast, the mutation of the uromodulin Asp196 156
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residue was associated with a milder maturation defect with some mutant uromodulin ex-
pressed at the plasma membrane in vitro       [10]   (  table 2  ); yet, it was associated with the most 
severe clinical outcome in its association with the early onset of ESRD (  fig. 3  ;   table 5  ). Thus, 
the basis of the effect of the   UMOD   genotype on development of ESRD cannot be explained 
by in vitro findings but remains to be elucidated. The association between genotype and pro-
gression to ESRD we found is based on a small number of cases and needs confirmation by 
a study including a much larger group of patients. 
    In conclusion, this report provides for the first time UAKD prevalence estimates for the 
general population and for RRT patients and it suggest that UAKD is indeed a rare disease. 
A rather simple systematic approach and a questionnaire may allow identification of hith-
erto undiagnosed UAKD RRT patients. Our data indicate that UMOD genotype may affect 
progression of renal disease to ESRD.
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